Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye diseases
Pharma
Apellis' weak quarter could signal Syfovre 'nadir': analysts
Apellis' geographic atrophy med Syfovre may have hit a performance “nadir” in 2024’s third quarter, one group of analysts contends.
Fraiser Kansteiner
Nov 5, 2024 3:41pm
EyePoint's Duravyu bounces back with promising DME data
Oct 28, 2024 1:11pm
Sales for Roche's Vabysmo rise again, but momentum is stalled
Jul 25, 2024 11:45am
Novo's Ozempic, Wegovy linked to eye problem: study
Jul 8, 2024 10:49am
Apellis takes it slow with first Syfovre DTC campaign
May 23, 2024 4:20pm
Apellis stock price slid 10% despite 'robust' growth of Syfovre
May 8, 2024 11:30am
